Banner Alzheimer's Institute
9
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
22.2%
2 terminated/withdrawn out of 9 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
100%
4 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses
Role: collaborator
The DIAGNOSE CTE Research Project-II
Role: collaborator
Mindfulness-Associated Brain Changes in Adults With Autism
Role: collaborator
Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain
Role: collaborator
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
Role: collaborator
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
Role: collaborator
Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)
Role: collaborator
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Role: collaborator
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Role: collaborator
All 9 trials loaded